Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| IL5 mAb | Monospecific antibody | Immunological disease | Asthma | Phase II | Global (except China) |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| IL5-H5214 | Human | Human IL-5 Protein, premium grade |  |
|
|
| EP-128 | Human | IL-5 [Biotinylated] : IL-5Rα Inhibitor Screening ELISA Kit | |||
| IL5-C52H3 | Cynomolgus | Cynomolgus IL-5 Protein, His Tag |  |
|
|
| IL5-M52H3 | Mouse | Mouse IL-5 Protein, His Tag (MALS verified) |  |
|
|
| IL5-R52H4 | Rabbit | Rabbit IL-5 Protein, His Tag |  |
|
|
| IL5-H82Q5 | Human | Biotinylated Human IL-5 Protein, His,Avitag™ |  |
|
|
| IL5-H52H3 | Human | Human IL-5 Protein, His Tag |  |
|
|
Loaded Human IL-5, His Tag, premium grade (Cat. No. IL5-H52H3) on NTA Biosensor, can bind Human IL-5 R alpha, Fc Tag with an affinity constant of 4.63 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Reslizumab | TRFK-5; CDP-835; SCH-5570; CEP-38072; CTx-55700; SCH-55700 | Approved | Teva Pharmaceutical Industries Ltd | Cinqair, Cinquil, Cinqaero | EU | Asthma | Teva Bv | 2016-03-23 | Loiasis; Hypereosinophilic Syndrome; Pulmonary Eosinophilia; Eosinophilic Esophagitis; Asthma; Bronchitis | Details |
| Mepolizumab | SB-240563; 240563 | Approved | Glaxosmithkline Plc | Bosatria, Nucala, 美泊利珠单抗 | EU | Eosinophilic Granuloma; Nasal Polyps; Hypereosinophilic Syndrome; Sinusitis | Glaxosmithkline Trading Services Ltd | 2015-11-04 | Hypereosinophilic Syndrome; Granulomatosis with Polyangiitis; Churg-Strauss Syndrome; Virus Diseases; Nasal Polyps; Chronic Urticaria; Eosinophilia; Eosinophilic Esophagitis; Asthma; Eosinophilic Granuloma; Bronchitis; Sinusitis; Pulmonary Disease, Chronic Obstructive; Fasciitis; Dermatitis, Atopic; Angioedema | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| long-acting anti-IL-5 mAb (GSK) | Phase 1 Clinical | Glaxosmithkline Plc | Asthma | Details | |
| Mepolizumab biosimilar (CTTQ Pharma) | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Hypereosinophilic Syndrome; Vasculitis; Nasal Polyps; Asthma; Eosinophilic Granuloma; Sinusitis | Details | |
| Mepolizumab biosimilar(Bio Thera Solutions) | Phase 1 Clinical | Bio-Thera Solutions Ltd | Autoimmune Diseases; Nasal Polyps; Sinusitis | Details | |
| SHR-1703 | SHR-1703 | Phase 2 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Asthma | Details |
| Recombinant anti-IL-5 humanized monoclonal antibody (Shanghai CP Guojian) | 610 | Phase 2 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Autoimmune Diseases; Asthma | Details |
| Depemokimab | GSK-294; GSK3511294; GSK294; GSK-3511294 | Phase 3 Clinical | Glaxosmithkline Plc | Hypereosinophilic Syndrome; Churg-Strauss Syndrome; Nasal Polyps; Vasculitis; Asthma; Eosinophilic Granuloma; Sinusitis | Details |
This web search service is supported by Google Inc.
A-Z
